IMRN

Immuron Limited is a biopharmaceutical company focused on developing and commercializing oral immunotherapies for the treatment of gut-mediated diseases. The company's lead products utilize polyclonal antibodies derived from hyperimmunized cows to target specific pathogens and inflammatory conditions in the gastrointestinal tract. Immuron's pipeline includes treatments for conditions such as traveler's diarrhea, Clostridium difficile infection, and fatty liver disease. The company's approach offers a non-systemic alternative to traditional antibiotics and anti-inflammatory drugs. Immuron markets its products in select territories while advancing clinical development programs for additional indications.